

# Bcl-2 antagonizes apoptotic cell death induced by two new ceramide analogues

Thomas Wieder<sup>a,b</sup>, Christoph C. Geilen<sup>a,\*</sup>, Thomas Kolter<sup>c</sup>, Farsaneh Sadeghlar<sup>c</sup>,  
Konrad Sandhoff<sup>c</sup>, Reinhard Brossmer<sup>d</sup>, Petra Ihrig<sup>d</sup>, David Perry<sup>e</sup>, Constantin E. Orfanos<sup>a</sup>,  
Yusuf A. Hannun<sup>e</sup>

<sup>a</sup>Department of Dermatology, University Medical Center Benjamin Franklin, The Free University of Berlin, Hindenburgdamm 30,  
D-12200 Berlin, Germany

<sup>b</sup>Institute of Molecular Biology and Biochemistry, University Medical Center Benjamin Franklin, The Free University of Berlin, Berlin, Germany

<sup>c</sup>Institute of Organic Chemistry and Biochemistry, University of Bonn, Bonn, Germany

<sup>d</sup>Institute of Biochemistry, University of Heidelberg, Heidelberg, Germany

<sup>e</sup>Department of Medicine, University Medical Center, Duke University, Durham, NC, USA

Received 6 May 1997; revised version received 29 May 1997

**Abstract** Ceramides which arise in part from the breakdown of sphingomyelin comprise a class of antiproliferative lipids and have been implicated in the regulation of programmed cell death better known as apoptosis. In the present study, two new synthetic ceramide analogues, *N*-thioacetyl sphingosine and FS-5, were used in Molt 4 cells to induce cell death. Besides their cytotoxic effects at concentrations  $\geq 14 \mu\text{M}$  the data obtained clearly show that both analogues induced apoptosis at concentrations below this critical concentration as assessed by trypan blue exclusion and cleavage of the death substrate poly-(ADP-ribose) polymerase (PARP). Additional experiments in bcl-2-transfected Molt 4 cells revealed that the apoptotic but not the lytic effects of the analogues were antagonized by the apoptosis inhibitor Bcl-2. Furthermore, neither *N*-thio-acetyl sphingosine nor FS-5 induced PARP cleavage in bcl-2-transfected Molt 4 cells indicating that the induction of apoptotic cell death by cell permeable ceramides is not due to unspecific disturbance of the cell membrane.

© 1997 Federation of European Biochemical Societies.

**Key words:** Apoptosis; Bcl-2; Sphingomyelin cycle; Synthetic ceramide

## 1. Introduction

Sphingolipids are well known structural components of the lipid bilayer of eukaryotic cell membranes. During the last few years, it has become increasingly obvious in different cell types that one member of this lipid class, sphingomyelin (SM), takes part in a novel pathway of cell signalling [1–5], and the term SM cycle has been coined for characterizing this function.  $1\alpha,25$ -Dihydroxyvitamin  $\text{D}_3$  was the first compound identified as an inducer of SM hydrolysis in HL-60 human leukemia cells leading to the generation of intracellular ceramide [1].

\*Corresponding author. Fax: (49) 30-8445-4262

**Abbreviations:**  $\text{C}_2\text{-Cer}=\text{O}$ , *N*-acetyl sphingosine;  $\text{C}_2\text{-Cer}=\text{S}$ , *N*-thio-acetyl sphingosine; DAG, diacylglycerol; DETAPAc, diethylenetriaminepentaacetic acid; ECL, enhanced chemiluminescence; EGTA, [ethylenbis(oxyethylenitrilo)]tetraacetic acid; FCS, fetal calf serum; FS-5, 4-dodecanoylamino-decan-5-ol;  $\text{IC}_{50}$ , half-inhibitory concentration;  $\text{LD}_{50}$ , half-lethal dose; Molt 4, human leukemia cell line; PAGE, polyacrylamide gel electrophoresis; PARP, poly-(ADP-ribose) polymerase; PBS, phosphate-buffered saline; RPMI, Roswell Park Memorial Institute; SDS, sodium dodecylsulfate; SM, sphingomyelin; TNF $\alpha$ , tumor necrosis factor  $\alpha$ ; TLC, thin layer chromatography

Using cell-permeable ceramide analogues, it was possible to mimic the effects of  $1\alpha,25$ -dihydroxyvitamin  $\text{D}_3$  on cell proliferation thereby confirming ceramide to be an important mediator of  $1\alpha,25$ -dihydroxyvitamin  $\text{D}_3$ -induced HL-60 cell differentiation [6]. In contrast to the mitogenic lipid mediator diacylglycerol (DAG) that arises from the hydrolysis of different glycerophospholipids [7,8] ceramide was described as a mediator of growth suppression and apoptosis [9].

Apoptosis, or programmed cell death, is a form of physiological cell death which can be distinguished from accidental destruction, or necrosis (for review, see [10]). Necrotic cell death occurs when a cell is severely injured, for example by a harsh physical insult, the cell begins to swell and the plasma membrane ruptures. On the other hand, cells undergoing apoptosis shrink and pull away from its neighbors. In apoptotic cells the plasma membrane remains intact and the chromatin frequently breaks into fragments that produce a ladder-like pattern. Recent experimental observations revealed that intracellular proteases might play a critical role in the initiation of apoptosis and the specific proteolytic cleavage of cellular proteins, such as poly-(ADP ribose) polymerase (PARP), has been identified during apoptosis in a wide variety of cells (for reviews, see [11,12]). Cleavage of PARP is catalyzed by a zymogen called Yama/CPP32 $\beta$  and leads to inactivation of this enzyme and generation of a 85 kDa apoptotic fragment [13]. Since ceramide was implicated in apoptotic cell death it is interesting that induction of the SM cycle or treatment of cells with cell-permeable ceramides also led to the cleavage of PARP and that this induction of PARP-cleavage was inhibited in bcl-2-transfected cells [14].

In the present study, the effects of two newly synthesized ceramide analogues, *N*-thio-acetyl sphingosine ( $\text{C}_2\text{-Cer}=\text{S}$ ) and FS-5 (for chemical structures, see Fig. 1), on the induction of apoptotic cell death and PARP-cleavage were investigated in Molt 4 and bcl-2-transfected Molt 4 cells. The results showed that treatment of Molt 4 cells with  $11.2 \mu\text{M}$   $\text{C}_2\text{-Cer}=\text{S}$  and  $11.2$ – $56.2 \mu\text{M}$  FS-5 induced cell death and cleavage of PARP after 13 h of incubation. Further experiments demonstrated that PARP-proteolysis was totally abolished in bcl-2-transfected Molt 4 cells.

## 2. Materials and methods

### 2.1. Materials

Polyclonal anti-PARP antibodies were a kind gift from Dr. Guy

Poirier (Quebec, Canada). DAG kinase was prepared as described [14,15]. Silica gel 60 TLC plates, solvents and reagents were from Whatman (Maidstone, UK). The ECL immunoblotting detection reagent was from Amersham (Cleveland, OH). [ $\gamma$ - $^{32}$ P]ATP (110 TBq/mmol) was obtained from NEN-DuPont (Bad Homburg, Germany). Hygromycin B was from Calbiochem (San Diego, CA). Trypan blue solution (0.4%) was from Sigma (St. Louis, MO).  $C_2$ -Cer=O was synthesized as described [16].  $C_2$ -Cer=O,  $C_2$ -Cer=S and FS-5 stock solutions were prepared in ethanol at concentrations of 10.0 mM, 28.0 mM and 28.1 mM, respectively. The purity of the used ceramide analogues was assessed by high-performance TLC using the solvent system chloroform/methanol (9:1, v/v) and compared with commercially available  $C_2$ -Cer=O (Alexis, Läufelfingen, Switzerland). In all cases the purity of the analogues was >98%. Ethanol (vehicle) was added to controls and was present at 0.2% or less in the experiments.

## 2.2. Synthesis of $C_2$ -Cer=S and FS-5

$C_2$ -Cer=S was synthesized from sphingosine and methyl dithioacetate [17,18]. The reaction product was fully characterized by NMR-spectroscopy and FAB MS. The detailed synthesis will be published elsewhere together with the preparation of additional analogues.

FS-5 (4-dodecanoylamino-decan-5-ol) was synthesized starting from 1-nitrobutane and *n*-hexanol according to [19], followed by acylation with dodecanoic acid. FS-5 was characterized by  $^1$ H-NMR-spectroscopy and high-resolution MS.

## 2.3. Cell culture

Human leukemia Molt 4 vector control cells and a bcl-2-transfected clone [15] were grown in RPMI selection medium supplemented with 10% heat-inactivated fetal calf serum (FCS) and 250  $\mu$ g/ml hygromycin B. For the experiments, vector control cells were used between passages 52 and 69, and bcl-2-transfected cells between passages 60 and 66.

## 2.4. Cytotoxicity assay

For this, Molt 4 vector control and bcl-2-transfected cells were seeded at a density of  $5 \times 10^5$  cells/ml in RPMI medium supplemented with 2% FCS. The cells were equilibrated at 37°C for 30 min and then treated with different concentrations of  $C_2$ -Cer=S and FS-5. In these experiments,  $C_2$ -Cer=O and ethanol were used as positive and negative controls. After 6 and 13 h of incubation, 100  $\mu$ l of a trypan blue solution (0.4%) were added to 500  $\mu$ l cell suspension and blue (dead) and unstained (living) cells were counted in a hemacytometer as described previously [20].

## 2.5. Determination of PARP cleavage

Cleavage of the death substrate PARP was determined as described by Tewari et al. [13]. For this, Molt 4 vector control and bcl-2-transfected cells were seeded at a density of  $5 \times 10^5$  cells/ml in RPMI medium supplemented with 2% FCS. The cells were equilibrated at 37°C for 30 min and then treated with different concentrations of  $C_2$ -Cer=S and FS-5. In these experiments,  $C_2$ -Cer=O and ethanol were used as positive and negative controls. After 6 and 13 h of incubation, 1 ml of each cell suspension was transferred to a reaction tube and the samples were centrifuged at  $350 \times g$ , 4°C for 5 min. The supernatants were discarded and 20  $\mu$ l reducing SDS sample buffer were added to the cell pellets. Proteins were separated by 6% SDS-PAGE [21] and transferred to nitrocellulose membrane. Then, PARP and the 85 kDa fragment of PARP were detected with a polyclonal rabbit anti-PARP antibody (1:2000) and the ECL immunoblotting detection kit from Amersham was used to visualize the proteins in question [22].

## 2.6. Determination of cellular ceramide

The ceramide assay was carried out by the method of Preiss et al. [23] using DAG kinase as described previously [24] with some modifications to simultaneously determine ceramide and diacylglycerol in the samples. In detail, Molt 4 vector control cells were seeded at a density of  $5 \times 10^5$  cells/ml in RPMI containing 2% FCS and equilibrated at 37°C for 30 min. Then, cells were treated for 3 and 5 h with 20  $\mu$ M etoposide, 11.2  $\mu$ M  $C_2$ -Cer=S, 11.2  $\mu$ M FS-5 or 0.2% ethanol. After incubation, cells were collected in a Beckmann CS-6 centrifuge at 1000 rpm for 5 min and lipids were extracted according to Bligh and Dyer [25]. The chloroform phase was transferred to glass tubes, dried under nitrogen and redissolved in 1 ml of chloroform/methanol (9:1, v/v). Subsequently, 800  $\mu$ l were taken for ceramide measure-

ments and 200  $\mu$ l were taken for the determination of phospholipids by the phosphate assay of Ames and Dubin using ammonium molybdate and ascorbic acid [26]. For ceramide measurements, the dried lipid extract was solubilized in 20  $\mu$ l of a detergent solution containing 7.5% octyl- $\beta$ -D-glucoside and 25 mM dioleoyl phosphatidylglycerol in 1 mM diethylenetriaminepentaacetic acid (DETAPAc) by sonication. 70  $\mu$ l of assay buffer containing 0.1 M imidazole-HCl, pH 6.6, 0.1 M NaCl, 25 mM  $MgCl_2$ , 2 mM [ethylene-bis(oxyethylenitrilo)] tetracetic acid (EGTA), 3 mM dithiothreitol and 5  $\mu$ g *sn*1,2-DAG kinase from *E. coli* was added. The reaction was started by addition of 10  $\mu$ l of a 2.5 mM [ $\gamma$ - $^{32}$ P]ATP solution (116000 dpm/nmol) in 0.1 M imidazole-HCl, pH 6.6, containing 1 mM DETAPAc. After incubation at 20°C for 30 min, the reaction was stopped by adding 2 ml of methanol, 1 ml of chloroform and 0.7 ml of water. The samples were stirred on a vortex mixer and phase separation was accomplished by addition of 1 ml of chloroform and 1 ml of water. After centrifugation, the upper phase was aspirated and 1.5 ml of the lower phase were transferred to another tube. The samples were dried under nitrogen and redissolved in 100  $\mu$ l of chloroform/methanol (9:1, v/v). Then, 20  $\mu$ l of each sample were spotted on silica gel 60 TLC plates. Plates were developed with chloroform/acetone/methanol/acetic acid/water (50:20:15:10:5, v/v) and subjected to autoradiography. Marked spots co-chromatographing with ceramide phosphate standards were scraped into scintillation vials and radioactivity in the silica gel scrapings was determined by liquid scintillation spectrometry. The amount of ceramide present in the samples was calculated from the sample volume and a ceramide standard curve. Determination of ceramide was linear over the range 20–640 pmol.

## 2.7. Other procedures

Statistical comparisons were made in these studies with Student's *t*-test.

## 3. Results and discussion

### 3.1. Cytotoxic effects of $C_2$ -Cer=S and FS-5 in Molt 4 cells

One possible mechanism mediating the biological properties of ceramide analogues might be a simple toxic effect, e.g. cellular lysis or unspecific disturbance of cellular membranes




Fig. 1. Chemical structures of  $C_2$ -Cer=O,  $C_2$ -Cer=S and FS-5.




Fig. 2. Cytotoxicity of C<sub>2</sub>-Cer=S and FS-5 in vector control and bcl-2 transfected Molt 4 cells. 5×10<sup>5</sup> vector control cells (A) and bcl-2-transfected cells (B) were treated with different concentrations of C<sub>2</sub>-Cer=S (□) and FS-5 (○). After 6 h (insert) or 13 h, viability of the cells was determined by trypan blue exclusion as described in Section 2. Values are given in % of control ± SD (n=4).

as has been described at high concentrations of the synthetic sphingolipid, *N*-acetyl-erythro-sphingosine-1-phosphocholine [20]. On the other hand, elevation of intracellular ceramide levels has been observed in many different forms of apoptosis and treatment of cells with truncated ceramide analogues was sufficient to induce apoptosis [27]. In our experimental system, FS-5 did not have an effect on viability after 6 h of incubation whereas C<sub>2</sub>-Cer=S showed acute toxic effects with a LD<sub>50</sub> of 28.0 μM (Fig. 2A, insert). At longer incubation periods of 13 h, the cytotoxic effect of C<sub>2</sub>-Cer=S was even more pronounced (LD<sub>50</sub>=22.4 μM) and incubation of Molt 4 vector control cells with 56.2 μM FS-5 significantly decreased viability to about 70% of control (Fig. 2A). As compared with the well known ceramide analogue, *N*-acetylsphingosine (C<sub>2</sub>-Cer=O) which decreased viability of Molt 4 cells to 11±7% at 23.4 μM, C<sub>2</sub>-Cer=S had a cytotoxic capacity of approximately 61% and FS-5 of 24%. These experiments revealed

that both ceramide analogues are biologically active compounds in Molt 4 cells.

### 3.2. Induction of PARP cleavage by C<sub>2</sub>-Cer=S and FS-5 in Molt 4 cells

Recently, it has been demonstrated that treatment of cells with truncated ceramides led to the proteolytic cleavage of the death substrate PARP [14] (see also Fig. 3). Therefore, the induction of PARP cleavage upon treatment with C<sub>2</sub>-Cer=S and FS-5 was investigated in Molt 4 cells. As shown in Fig. 3, a weak signal of the 85 kDa fragment of PARP is seen after 6 h of incubation with 11.2 μM C<sub>2</sub>-Cer=S and 11.2–56.2 μM FS-5 when the cell lysates were analyzed by Western blot. After 13 h of incubation, the 85 kDa fragment accumulated in C<sub>2</sub>-Cer=S- and FS-5-treated cells thereby confirming that the cells were driven into apoptosis. In support of the data on viability described in the previous section only concentrations




Fig. 3. Induction of PARP cleavage by  $C_2$ -Cer=S and FS-5 in Molt 4 cells.  $5 \times 10^5$  vector control cells were treated with 11.7  $\mu$ M  $C_2$ -Cer=O or with different concentrations of  $C_2$ -Cer=S or FS-5. After 6 h and 13 h of incubation, cleavage of the death substrate PARP was assessed by Western blot analysis as described in Section 2. The experiment was repeated and similar results were obtained.

< 14  $\mu$ M  $C_2$ -Cer=S induced PARP-cleavage whereas the 85 kDa fragment was not observed in cells treated with  $C_2$ -Cer=S concentrations of 28.0 and 55.9  $\mu$ M (Fig. 3). In additional experiments, we used  $C_2$ -Cer=S concentrations below 28.0  $\mu$ M, and 11.2  $\mu$ M was found to be the optimum concentration (data not shown). In contrast, FS-5 showed concentration-dependent effects on PARP-cleavage and 56.2  $\mu$ M FS-5 was the most efficient concentration used. Interestingly, it was reported that only ceramides containing a 4,5-trans-double bond induce apoptosis [16]. Thus, FS-5 is the first compound with pro-apoptotic properties lacking this structural feature.

### 3.3. Effects of $C_2$ -Cer=S and FS-5 on endogenous ceramide levels in Molt 4 cells

Generation of ceramides has been reported as a common cellular response of different cell types after challenge with death-inducing agents, such as  $TNF\alpha$  [28,29], interleukin-1 $\beta$  [30], ionizing radiation [31] and therapeutic agents, such as retinoic acid [3] and 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> [32]. To ex-

clude the possibility that the induction of PARP-cleavage by  $C_2$ -Cer=S and FS-5 is indirectly mediated by an increase in endogenous ceramide levels, cellular ceramide was measured in extracts from Molt 4 cells which had been treated with 11.2  $\mu$ M of the respective ceramide analogue for 3 and 5 h using DAG kinase. However, neither  $C_2$ -Cer=S nor FS-5 significantly increased ceramide levels in Molt 4 cells (Table 1).

### 3.4. Bcl-2 antagonizes $C_2$ -Cer=S- and FS-5-induced cytotoxicity and PARP cleavage

The apoptosis inhibitors Bcl-2 and Bcl-XL have been shown to block ceramide-induced cell death in lymphoid cell lines [14,27,33,34]. To study the specificity of  $C_2$ -Cer=S and FS-5-induced cell death we used Molt 4 cells which had been transfected with bcl-2. As shown in Fig. 2B, bcl-2-transfected Molt 4 cells were less sensitive to treatment with  $C_2$ -Cer=S and FS-5. In the case of FS-5 the cytotoxic effect occurring after 13 h in control vector cells was totally blocked in bcl-2-transfected cells. On the other hand, only the cytotoxic effect induced by 14.0  $\mu$ M  $C_2$ -Cer=S was antagonized in bcl-2-transfected cells whereas 28.0 and 55.9  $\mu$ M  $C_2$ -Cer=S still killed the cells (Fig. 2B). This failure of anti-apoptotic proteins, such as Bcl-XL, to block the cytotoxic effect of truncated ceramides at high concentrations has also been observed in endothelial cells [34]. Further experiments revealed that  $C_2$ -Cer=S and FS-5-induced cleavage of PARP was totally abolished in bcl-2-transfected Molt 4 cells (Fig. 4) suggesting that overexpression of Bcl-2 interrupts the pro-apoptotic effects of both ceramide analogues. Since it was shown previously that bcl-2-transfection did not interfere with ceramide-production via the sphingomyelin cycle [15] these data are consistent with the hypothesis that Bcl-2 acts downstream of ceramide formation.

In summary, we provide data about two newly synthesized ceramide analogues with different biological activities. The sulfur-containing  $C_2$ -Cer=S induced apoptotic cell death at low concentrations as shown by PARP-cleavage. However, at

Table 1  
Effects of etoposide,  $C_2$ -Cer=S and FS-5 on endogenous ceramide levels in Molt 4 cells

Treatment	Ceramide (% of control)	
	Incubation (3 h)	(5 h)
Control	100 $\pm$ 5	100 $\pm$ 1320
$\mu$ M etoposide	95 $\pm$ 23	149 $\pm$ 6*
11.2 $\mu$ M $C_2$ -Cer=S	88 $\pm$ 30	113 $\pm$ 18
11.2 $\mu$ M FS-5	98 $\pm$ 21	104 $\pm$ 16

Molt 4 vector control cells were incubated for 3 and 5 h in medium containing 20  $\mu$ M etoposide, 11.2  $\mu$ M  $C_2$ -Cer=S, 11.2  $\mu$ M FS-5 or 0.2% EtOH as control. After treatment, cells were collected and ceramide and lipid phosphate were analyzed as described in Section 2. Values of endogenous ceramide are given in % of control  $\pm$  SD ( $n$  = 3). Ceramide levels in control cells were  $4.0 \pm 1.1$  pmol/nmol phosphate.

\*Significantly different from controls at  $P$  < 0.01.




Fig. 4. Inhibition of  $C_2$ -Cer=S- and FS-5-induced PARP cleavage in bcl-2 transfected Molt 4 cells.  $5 \times 10^5$  bcl-2-transfected cells were treated with  $11.7 \mu\text{M}$   $C_2$ -Cer=O or with different concentrations of  $C_2$ -Cer=S or FS-5. Additionally, vector control cells that had been treated with  $11.7 \mu\text{M}$   $C_2$ -Cer=O were used as positive controls. After 6 h and 13 h of incubation, cleavage of the death substrate PARP was assessed by Western blot analysis as described in Section 2. The experiment was repeated and similar results were obtained.

concentrations  $\geq 28.0 \mu\text{M}$  the cell ghost-like morphology of the cells indicated membrane damage and the cytotoxic effects of  $C_2$ -Cer=S were no longer accompanied by an induction of PARP-cleavage and not inhibited by Bcl-2 thereby suggesting cell lysis. On the other hand, the ceramide analogue FS-5 which is blocked at the C1-position of the sphingosine backbone specifically induced apoptosis at concentrations  $\leq 56.2 \mu\text{M}$ . From these data, we suggest that the concept of using synthetic ceramide analogues may lead to significant insights into ceramide-mediated signalling.

**Acknowledgements:** The work was supported by research and travel grants from the Deutsche Forschungsgemeinschaft (Ge 641/3-3 and SFB 366; Ko 1576/1-1 and SFB 284).

## References

- [1] Okazaki, T., Bell, R.M. and Hannun, Y.A. (1989) *J. Biol. Chem.* 264, 19076–19080.
- [2] Mathias, S., Younes, A., Kan, C.-C., Orlow, I., Joseph, C. and Kolesnick, R.N. (1993) *Science* 259, 519–522.
- [3] Riboni, L., Prinetti, A., Bassi, R., Caminiti, A. and Tettamanti, G. (1995) *J. Biol. Chem.* 270, 26868–26875.
- [4] Hannun, Y.A. (1996) *Science* 274, 1855–1859.
- [5] Testi, R. (1996) *Trends Biochem. Sci.* 21, 468–471.
- [6] Okazaki, T., Bielawska, A., Bell, R.M. and Hannun, Y.A. (1990) *J. Biol. Chem.* 265, 15823–15831.
- [7] Nishizuka, Y. (1992) *Science* 258, 607–614.
- [8] Exton, J.H. (1994) *Biochem. Biophys. Acta* 1212, 26–42.
- [9] Obeid, L.A. and Hannun, Y.A. (1995) *J. Cell Biochem.* 58, 191–198.
- [10] Thompson, C.B. (1995) *Science* 267, 1456–1462.
- [11] Martin, S.J. and Green, D.R. (1995) *Cell* 82, 349–352.
- [12] Patel, T., Gores, G.J. and Kaufmann, S.H. (1996) *FASEB J.* 10, 587–597.
- [13] Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirier, G.G., Salvesen, G.S. and Dixit, V.M. (1995) *Cell* 81, 801–809.
- [14] Smyth, M.J., Perry, D.K., Zhang, J., Poirier, G.G., Hannun, Y.A. and Obeid, L.M. (1996) *Biochem. J.* 316, 25–28.
- [15] Zhang, J., Alter, N., Reed, J.C., Borner, C., Obeid, L.M. and Hannun, Y.A. (1996) *Proc. Natl. Acad. Sci. USA* 93, 5325–5328.
- [16] Bielawska, A., Crane, H.M., Liotta, D., Obeid, L.M. and Hannun, Y.A. (1993) *J. Biol. Chem.* 268, 26226–26232.
- [17] Isecke, R. and Brossmer, R. (1993) *Tetrahedron* 49, 10009–10016.
- [18] Isecke, R. and Brossmer, R. (1994) *Tetrahedron* 50, 7445–7460.
- [19] Kolter, T., van Echten-Deckert, G. and Sandhoff, K. (1994) *Tetrahedron* 50, 13425–13432.
- [20] Wieder, T., Perlitz, C., Wieprecht, M., Huang, R.T.C., Geilen, C.C. and Orfanos, C.E. (1995) *Biochem. J.* 311, 873–879.
- [21] Laemmli, U.K. (1970) *Nature* 227, 680–685.
- [22] Wieder, T., Geilen, C.C., Wieprecht, M., Becker, A. and Orfanos, C.E. (1994) *FEBS Lett.* 345, 207–210.
- [23] Preiss, J., Loomis, C.R., Bishop, W.R., Stein, R., Nidel, J.E. and Bell, R.M. (1986) *J. Biol. Chem.* 261, 8597–8600.
- [24] Geilen, C.C., Wieder, T. and Reutter, W. (1992) *J. Biol. Chem.* 267, 6719–6724.
- [25] Bligh, E.G. and Dyer, W.J. (1959) *Can. J. Biochem. Physiol.* 37, 911–917.
- [26] Ames, B. and Dubin, D.T. (1960) *J. Biol. Chem.* 235, 769–775.
- [27] Geley, S., Hartmann, B.L. and Kofler, R. (1997) *FEBS Lett.* 400, 15–18.
- [28] Obeid, L.M., Linardic, C.M., Karolak, L.A. and Hannun, Y.A. (1993) *Science* 259, 1769–1771.
- [29] Modur, V., Zimmermann, G.A., Prescott, S.M. and McIntyre, T.M. (1996) *J. Biol. Chem.* 271, 13094–13102.
- [30] Masamune, A., Igarashi, Y. and Hakomori, S. (1996) *J. Biol. Chem.* 271, 9368–9375.
- [31] Verheij, M., Bose, R., Lin, X.H., Yao, B., Jarvis, W.D., Grant, S., Birrer, M.J., Szabo, E., Zon, L.I., Kyriakis, J.M., Haimovitz-Friedman, A., Fuks, Z. and Kolesnick, R. (1996) *Nature* 380, 75–79.
- [32] Geilen, C.C., Bektas, M., Wieder, T. and Orfanos, C.E. (1996) *FEBS Lett.* 378, 88–92.
- [33] Fang, W., Rivard, J.J., Ganser, J.A., LeBien, T.W., Nath, K.A., Mueller, D.L. and Behrens, T.W. (1995) *J. Immunol.* 155, 66–75.
- [34] Karsan, A., Yee, E. and Harlan, J.M. (1996) *J. Biol. Chem.* 271, 27201–27204.